Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1995
Business Overview: ASHS provides shared diagnostic imaging services (MRI, CT, Ultrasound, Nuclear Medicine) and radiotherapy (Gamma Knife) to approximately 220 hospitals and medical centers across 22 states. The company operates primarily through mobile units and shared-service contracts to allow providers to access high-end technology without capital ownership.
Key Financial Metrics
| Metric | 1995 | 1994 | 1993 |
|---|---|---|---|
| Medical Services Revenue | $34,077,000 | $38,545,000 | $39,485,000 |
| Net Income (Loss) | $7,344,000 | ($5,175,000) | ($15,644,000) |
| Loss Before Extraordinary Items | ($12,459,000) | ($5,537,000) | ($15,644,000) |
| Extraordinary Gain (Debt Restructuring) | $19,803,000 | $362,000 | $0 |
| EPS (Diluted) - Net Income | $1.75 | ($1.80) | ($5.46) |
| EPS (Diluted) - Pre-Extraordinary | ($2.96) | ($1.93) | ($5.46) |
| Cash and Cash Equivalents | $452,000 | $1,225,000 | $957,000 |
| Working Capital Deficiency | ($6,793,000) | ($33,369,000) | ($56,518,000) |
| Stockholders' Equity (Net Capital Deficiency) | ($10,576,000) | ($22,341,000) | ($17,754,000) |
| Total Debt & Capital Lease Obligations | $34,845,000 | $43,959,000 | $48,529,000 |
Note: Total Debt includes current and long-term portions of debt and obligations under capital leases.
Material Changes vs. Prior Period
- Revenue Decline: Medical services revenue decreased 11.6% to $34.1 million, primarily due to the December 1994 sale of respiratory therapy contracts and a continued decline in non-MRI services (CT, Ultrasound, Nuclear Medicine) caused by market competition and equipment cost reductions allowing hospitals to purchase their own units.
- Operating Loss: The company reported a loss from operations of $12.9 million before extraordinary items, compared to $9.0 million in 1994. This was driven by a $4.4 million impairment charge (FAS 121 adoption) and $2.7 million in stock-based compensation.
- Debt Restructuring: In May 1995, the company repurchased approximately 96% of its Senior Subordinated Notes. This resulted in a $19.8 million extraordinary gain, turning a significant operating loss into a net profit for the year.
- Liquidity: Cash and cash equivalents declined to $452,000. The company maintains a working capital deficiency of $6.8 million and a net capital deficiency of $10.6 million.
Outlook, Risks, and Management Commentary
- Going Concern: The independent auditors have issued a "going concern" opinion. The company has incurred substantial losses, has a significant working capital deficiency, and lacks sufficient cash resources to repay debt obligations at maturity without new financing.
- Listing Status: The company's common stock is at risk of delisting from the American Stock Exchange (AMEX) and Pacific Stock Exchange (PSE) due to net capital deficiency and low share price ($1.25 as of March 27, 1996).
- Management Strategy: To meet obligations, management plans to reduce expenses, sell non-essential assets, negotiate with creditors, and exchange equity for debt. There is no assurance these measures will succeed.
- Regulatory Risks: The company faces risks from federal anti-kickback statutes, physician self-referral laws (Stark II), and potential changes in Medicare/Medicaid reimbursement rates (DRG systems).
- Unusual Items: The 1995 results are heavily skewed by the debt restructuring gain. Excluding this, the company's core operations remain unprofitable. Significant stock-based compensation ($2.7 million) was issued to the CEO for personal guarantees of new credit facilities.
Investor Verification Checklist
- Debt Covenants: Verify the specific terms of the new credit facilities (New Revolver, Term Loan, Gamma Knife Loan) and the extent of personal guarantees provided by the CEO.
- Asset Impairment: Review the methodology used for the $4.4 million FAS 121 impairment charge to ensure it accurately reflects the fair value of MRI and CT assets.
- Listing Compliance: Monitor the status of the AMEX and PSE reviews regarding the company's continued listing eligibility.
- Cash Flow Sufficiency: Assess whether the projected cash flows from operations and asset sales are sufficient to cover the $8.3 million in scheduled capital lease payments and $4.8 million in other debt payments due in 1996.
- Related Party Transactions: Scrutinize the terms of the Gamma Knife joint venture and the stock options granted to the CEO, which represent a significant portion of the company's equity.